Buscar.
Buscar.
Resultados de la búsqueda 35
AmoyDx® Essential NGS panel got approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
Noticias & eventos
2018 AmoyDx Distributors Annual Meeting successfully held in Shanghai
November 11, 2018 (Shanghai, China) AmoyDx Distributors Annual Meeting 2018 was held in Shanghai on November 8, 2018. 34 delegates from 19 countries gathered together to get the latest market
Noticias & eventos
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA(National Medical Products Administration)approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
Noticias & eventos
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us.  The exhibition details are below.
Noticias & eventos
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017 was held in Xiamen, China on December 4. Distributors from different countries gathered to get the recent update on precision oncology
Noticias & eventos
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
Noticias & eventos
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
The 18th World Conference on Lung Cancer (WCLC) was held in Yokohama, Japan this week. It is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by
Noticias & eventos
Visit AmoyDx at WCLC 2017 of IASLC in Japan
Amoy Diagnostics will be exhibiting at the IASLC WCLC 2017 in Yokohama, Japan. Welcome to visit us.
Noticias & eventos
AmoyDx attended News Conference of Xalkori ROS1 approval in Japan
On June 23, Pfizer Oncology and Merck KGaA held a News Conference in Tokyo launching Xalkori (Crizotinib) ROS1 approval for additional indication. Xalkori, as a lung cancer targeted drug developed by Pfizer.
Noticias & eventos
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
Noticias & eventos
AmoyDx in European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance
Noticias & eventos
Visit AmoyDx at ELCC 2017 in Switzerland
Amoy Diagnostics will be exhibiting at the ELCC 2017 in Geneva, Switzerland. Welcome to visit us. The exhibition details are below.
Noticias & eventos
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
Noticias & eventos
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
Noticias & eventos
Amoy Diagnostics Achieved CFDA Approval For Its EGFR&ALK&ROS1 Testing Kit
Amoy Diagnostics Co., Ltd. (AmoyDx), a provider of oncology molecular diagnostics products and services, announced today that it has got Chinese FDA (CFDA) approval for its multiple gene mutations detection
Noticias & eventos
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
Noticias & eventos
ROS1 Gene Fusions Detection Kit
PRODUCTOS
ALK Gene Fusions and ROS1 Gene Fusions Detection Kit
PRODUCTOS
EGFR/ALK/ROS1 Mutations Detection Kit
PRODUCTOS
Essential NGS Panel
A precise NGS panel, focusing on 10 genes which have clear evidence to the targeted therapy.
PRODUCTOS
ROS1-L1-06 AR-L1-01 EAR-L1-01 Prevalence of ROS1 fusion in Chinese patients with non‐small cell lung cancer
Descargar
ROS1-L2-01 Testing for ROS1 in non-small cell lung cancer a review with recommendations
Descargar
EGFR-L2-07 KRAS-L2-03 BRAF-L2-03 PIK3CA-L2-01 ROS1-L2-02 Molecular alterations and clinical prognostic factors for
Descargar
ROS1-L1-05 A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
Descargar
ROS1-L1-04 Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer
Descargar
MSDS-ROS1-201804
Descargar
ROS1-L1-03 Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
Descargar
ROS1-L1-02 Detection of lung adenocarcinoma with ROS1 rearrangement by IHC , FISH , and RT-PCR and analysis of its
Descargar
ROS1-L1-01 ROS1 fusions in Chinese patients with non-small-cell lung cancer
Descargar
AmoyDx® EGFR.ALK.ROS1 Mutations Detection Kit-P2.2-8T
Descargar
AmoyDx® ALK Gene Fusions and ROS1 Gene Fusions Detection Kit-P2.0-8T
Descargar
AmoyDx® ROS1 Gene Fusions Detection Kit-B2.1-12T
Descargar
MSDS-EGFR ALK ROS1-201804
Descargar
4. ROS1-2017.9
Descargar
MSDS-ALK&ROS1-201804
Descargar
no más...
AmoyDx® Essential NGS panel got approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
Noticias & eventos
2018 AmoyDx Distributors Annual Meeting successfully held in Shanghai
November 11, 2018 (Shanghai, China) AmoyDx Distributors Annual Meeting 2018 was held in Shanghai on November 8, 2018. 34 delegates from 19 countries gathered together to get the latest market
Noticias & eventos
Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit
Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA(National Medical Products Administration)approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.
Noticias & eventos
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us.  The exhibition details are below.
Noticias & eventos
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017 was held in Xiamen, China on December 4. Distributors from different countries gathered to get the recent update on precision oncology
Noticias & eventos
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
Noticias & eventos
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
The 18th World Conference on Lung Cancer (WCLC) was held in Yokohama, Japan this week. It is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by
Noticias & eventos
Visit AmoyDx at WCLC 2017 of IASLC in Japan
Amoy Diagnostics will be exhibiting at the IASLC WCLC 2017 in Yokohama, Japan. Welcome to visit us.
Noticias & eventos
AmoyDx attended News Conference of Xalkori ROS1 approval in Japan
On June 23, Pfizer Oncology and Merck KGaA held a News Conference in Tokyo launching Xalkori (Crizotinib) ROS1 approval for additional indication. Xalkori, as a lung cancer targeted drug developed by Pfizer.
Noticias & eventos
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
Noticias & eventos
AmoyDx in European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance
Noticias & eventos
Visit AmoyDx at ELCC 2017 in Switzerland
Amoy Diagnostics will be exhibiting at the ELCC 2017 in Geneva, Switzerland. Welcome to visit us. The exhibition details are below.
Noticias & eventos
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
Noticias & eventos
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
Noticias & eventos
Amoy Diagnostics Achieved CFDA Approval For Its EGFR&ALK&ROS1 Testing Kit
Amoy Diagnostics Co., Ltd. (AmoyDx), a provider of oncology molecular diagnostics products and services, announced today that it has got Chinese FDA (CFDA) approval for its multiple gene mutations detection
Noticias & eventos
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine
Noticias & eventos
no más...
Investigación
* Información requerida
Gestiona la información de tu cuenta
cambia tu contraseña